These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Defective myocardial carnitine metabolism in congestive heart failure secondary to dilated cardiomyopathy and to coronary, hypertensive and valvular heart diseases. Regitz V; Shug AL; Fleck E Am J Cardiol; 1990 Mar; 65(11):755-60. PubMed ID: 2316456 [TBL] [Abstract][Full Text] [Related]
3. [Myocardial catecholamine content in heart failure--I: Regional distribution in explanted hearts. Comparison between dilated cardiomyopathy and coronary heart disease]. Regitz V; Sasse S; Bossaller C; Strasser R; Schüler S; Hetzer R; Fleck E Z Kardiol; 1989 Dec; 78(12):751-8. PubMed ID: 2623916 [TBL] [Abstract][Full Text] [Related]
4. Metabolic alterations in end-stage and less severe heart failure--myocardial carnitine decrease. Regitz V; Bossaller C; Strasser R; Müller M; Shug AL; Fleck E J Clin Chem Clin Biochem; 1990 Sep; 28(9):611-7. PubMed ID: 2290080 [TBL] [Abstract][Full Text] [Related]
5. The myocardial distribution and plasma concentration of carnitine in patients with mitral valve disease. Nakagawa T; Sunamori M; Suzuki A Surg Today; 1994; 24(4):313-7. PubMed ID: 8038505 [TBL] [Abstract][Full Text] [Related]
6. Myocardial carnitine metabolism in congestive heart failure induced by incessant tachycardia. Pierpont ME; Foker JE; Pierpont GL Basic Res Cardiol; 1993; 88(4):362-70. PubMed ID: 8240228 [TBL] [Abstract][Full Text] [Related]
7. Angiotensin II receptor type 1 mRNA is upregulated in atria of patients with end-stage heart failure. Kaprielian RR; Dupont E; Hafizi S; Poole-Wilson PA; Khaghani A; Yacoub MH; Severs NJ J Mol Cell Cardiol; 1997 Aug; 29(8):2299-304. PubMed ID: 9281460 [TBL] [Abstract][Full Text] [Related]
8. [Carnitine metabolism--changes in the end stage of dilated cardiomyopathy and ischemic heart muscle disease]. Regitz V; Müller M; Schüler S; Yankah CA; Hetzer R; Shug AL; Fleck E Z Kardiol; 1987; 76 Suppl 5():1-8. PubMed ID: 3324528 [TBL] [Abstract][Full Text] [Related]
9. Endothelin receptors in the failing and nonfailing human heart. Pönicke K; Vogelsang M; Heinroth M; Becker K; Zolk O; Böhm M; Zerkowski HR; Brodde OE Circulation; 1998 Mar; 97(8):744-51. PubMed ID: 9498537 [TBL] [Abstract][Full Text] [Related]
10. Selective induction of matrix metalloproteinases and tissue inhibitor of metalloproteinases in atrial and ventricular myocardium in patients with atrial fibrillation. Mukherjee R; Herron AR; Lowry AS; Stroud RE; Stroud MR; Wharton JM; Ikonomidis JS; Crumbley AJ; Spinale FG; Gold MR Am J Cardiol; 2006 Feb; 97(4):532-7. PubMed ID: 16461051 [TBL] [Abstract][Full Text] [Related]
11. Elevation of circulating and ventricular adrenomedullin in human congestive heart failure. Jougasaki M; Wei CM; McKinley LJ; Burnett JC Circulation; 1995 Aug; 92(3):286-9. PubMed ID: 7634439 [TBL] [Abstract][Full Text] [Related]
12. Plasma carnitine levels as a marker of impaired left ventricular functions. El-Aroussy W; Rizk A; Mayhoub G; Aleem SA; El-Tobgy S; Mokhtar MS Mol Cell Biochem; 2000 Oct; 213(1-2):37-41. PubMed ID: 11129956 [TBL] [Abstract][Full Text] [Related]
14. Angiotensin II receptors in normal and failing human hearts. Urata H; Healy B; Stewart RW; Bumpus FM; Husain A J Clin Endocrinol Metab; 1989 Jul; 69(1):54-66. PubMed ID: 2732298 [TBL] [Abstract][Full Text] [Related]
15. Differential functional expression of human myocardial G protein receptor kinases in left ventricular cardiac diseases. Dzimiri N; Muiya P; Andres E; Al-Halees Z Eur J Pharmacol; 2004 Apr; 489(3):167-77. PubMed ID: 15087239 [TBL] [Abstract][Full Text] [Related]
17. Regional heterogeneity of decreased myocardial norepinephrine and increased lipid peroxidation levels in patients with end-stage failing heart secondary to dilated or ischemic cardiomyopathy. Rochette L; Tatou E; Vergely C; Maupoil V; Bouchot O; Mossiat C; Jazayeri S; Benkhadra S; Brenot R; Girard C; David M J Heart Lung Transplant; 2008 Jul; 27(7):767-74. PubMed ID: 18582807 [TBL] [Abstract][Full Text] [Related]
18. Myocardial carnitine and carnitine palmitoyltransferase deficiencies in patients with severe heart failure. Martín MA; Gómez MA; Guillén F; Börnstein B; Campos Y; Rubio JC; de la Calzada CS; Arenas J Biochim Biophys Acta; 2000 Nov; 1502(3):330-6. PubMed ID: 11068176 [TBL] [Abstract][Full Text] [Related]
19. Altered cardiac annexin mRNA and protein levels in the left ventricle of patients with end-stage heart failure. Song G; Campos B; Wagoner LE; Dedman JR; Walsh RA J Mol Cell Cardiol; 1998 Mar; 30(3):443-51. PubMed ID: 9515022 [TBL] [Abstract][Full Text] [Related]
20. Nutritional supplementation with MyoVive repletes essential cardiac myocyte nutrients and reduces left ventricular size in patients with left ventricular dysfunction. Jeejeebhoy F; Keith M; Freeman M; Barr A; McCall M; Kurian R; Mazer D; Errett L Am Heart J; 2002 Jun; 143(6):1092-100. PubMed ID: 12075268 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]